Facioscapulohumeral dystrophy: A distinct regional myopathy with a novel molecular pathogenesis

Annals of Neurology

Volumn 43, Issue 3, 1998, Pages 279-282

  Tawil, Rabi ^a   Figlewicz, Denise A ^a   Griggs, Robert C ^a   Weiffenbach, Barbara ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b GENOME THERAPEUTICS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; CHROMOSOME 4Q; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FAMILY HISTORY; GENE DELETION; GENE LOCUS; GENETIC LINKAGE; HUMAN; MUSCLE WEAKNESS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CHROMOSOME MAPPING; DISEASE MODELS, ANIMAL; GENE DELETION; GENOTYPE; HUMANS; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, ANIMAL; PHENOTYPE;

EID: 0031915927     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430303     Document Type: Review

References (32)

1. Padberg G. Facioscapulohumeral disease. Leiden, The Netherlands: University of Leiden, 1982. Thesis
2. Tawil R, Griggs RC. Facioscapulohumeral muscular dystrophy. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, eds. The molecular and genetic basis of neurological disease. Boston: Butterworth-Heinemann, 1997:931-938
3. Padberg G, Brouwer OF, de Keizer RJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995;Suppl 2:S73-S80
4. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. Brain 1987;110:631-684
5. Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: evidence for selective genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990;15:292-299
6. DeVisser M, DeVoogt GW, La Riviere GV. The heart in Becker muscular dystrophy, facioscapulohumeral muscular dystrophy and Bethlem myopathy. Muscle Nerve 1992;15:591-596
7. The FSH-DY Group. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. Neurology 1997; 48:38-46
8. Tawil R, Myers GJ, Weiffenbach B, Griggs RC. Scapuloperoneal syndromes: absence of linkage to the 4q35 FSHD locus. Arch Neurol 1995;52:1069-1072
9. Wijmenga C, Hewitt JE, Sandkuijl LAX, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 1992;2:26-30
10. Wijmenga C, Padberg GW, Moerer P, et al. Mapping of facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by multipoint linkage analysis and in situ hybridization. Genomics 1991;9:570-575
11. Winokur ST, Bengtsson U, Feddersen J, et al. The DNA rearrangement associated with facioscapulohumeral muscular dystrophy involves a heterochromatin-associated repetitive element: implications for a role of chromatin structure in the pathogenesis of the disease. Chromosome Res 1994;2:225-234
12. van Deutekom JCT, Lemmers R, Grewal PK, et al. Identification of the first gene (FRG 1) from the FSHD region on human chromosome 4q35. Hum Mol Genet 1996;5:581-590
13. van Deutekom JCT, van Geel M, van Staalduinen A, et al. A novel β-tubulin gene (TUBrq) in the chromosome 4q35 region: a candidate gene for FSHD1? (In press)
14. Deidda G, Cacurri S, Piazzo N, Felicetti L. Direct detection of 4q35 rearrangements implicated in facioscapulohumeral muscular dystrophy (FSHD). J Med Genet 1996;33:361-365
15. van Deutekom JC, Bakker E, et al. Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. Hum Mol Genet 1996;5:1997-2003
16. Gilbert JR, Stajich JM, Wall S, et al. Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD). Am J Hum Genet 1993;53:401-408
17. Mathews KD, Rapisanta D, Bailey HL, et al. Phenotypic and pathologic evaluation of the myd mouse: a candidate model for facioscapulohumeral dystrophy. J Neuropathol Exp Neurol 1995;54:601-606
18. Zatz M, Suely SK, Passos-Bueno MR, et al. High proportion of new mutation and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet 1995;56:99-105
19. Lunt PW, Jardine PE, Koch MC, et al. Correlation between fragment size at D4F104S1 and age of onset or at wheelchair use, with a possible generational effect, accounts for much phentotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet 1995;4:951-958
20. Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and association of deletion size with severity of facioscapulohumeral muscular dystrophy. Ann Neurol 1996;39:744-748
21. Bates D, Stevens JC, Hodgson P. Polymyositis with involvement of facial and distal musculature: one form of facioscapulohumeral syndrome? J Neurol Sci 1973;19:105-108
22. Munsat TL, PiperD, Cancilla P, et al. Inflammatory myopathy with facioscapulohumeral distribution. Neurology 1972;22: 335-347
23. Wulf JD, Lin JT, Kepes JJ. Inflammatory facioscapulohumeral muscular dystrophy and Coats syndrome. Ann Neurol 1982;12: 398-401
24. Mendell JR, Moxley RT III, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne muscular dystrophy. N Engl J Med 1989;320:1592-1597
25. Tawil R, McDermott MP, Pandya S, et al. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. Neurology 1997;48:46-49
26. Kissel J, Mendell JR, Griggs RC, et al. Open-label clinical trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology 1997;48:A194
27. Emery PW, Rothwell NJ, Stock MJ, Winter PD. Chronic effects of beta 2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep 1984;4:83-91
28. Martineau L, Little RA, Rothwell NJ, Fisher MI. Clenbuterol, a beta 2-adrenergic agonist, reverses muscle wasting due to scald injury in the rat. Burns 1993;19:26-34
29. Zeman RJ, Ludemann R, Etlinger JD. Clenbuterol, a beta 2-agonist, retards atrophy in denervated muscles. Am J Physiol 1987;252:E152-E155
30. Rothwell NJ, Stock MJ. Modification of body composition by clenbuterol in normal and dystrophic (mdx) mice. Biosci Rep 1985;5:755-760
31. Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci 1992;83:615-621
32. Maltin CA, Delday MI, Watson JS, et al. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci 1993;84:651-654